Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived allogeneic mesenchymal stem cells
- Development stage
- Phase 1
- Lead developer
- Vcanbio Cell & Gene Engineering
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
**Umbilical cord-derived allogeneic mesenchymal stem cells (UC-MSCs)** are mesenchymal stromal/stem cells isolated from human umbilical cord tissue (commonly from Wharton’s jelly) and expanded in vitro for therapeutic use. These cells are characterized by their immunomodulatory, anti-inflammatory, antifibrotic, and proangiogenic properties, making them candidates for the treatment of autoimmune diseases, inflammatory conditions, and tissue repair. UC-MSCs can regulate immune response, reduce pathological inflammation and fibrosis, and secrete trophic factors, promoting tissue repair and regeneration. The therapy involves administering stem cells derived from donor umbilical cords to unrelated recipients (allogeneic). UC-MSCs have been tested in clinical trials for systemic lupus erythematosus, Crohn's disease, multiple sclerosis, idiopathic pulmonary fibrosis, immune thrombocytopenia, and moderate-to-severe COVID-19, among other conditions. Their mechanisms are primarily paracrine, influencing local immune cells and tissue repair processes via the release of anti-inflammatory cytokines, growth factors, and exosomes[1][2][3][4][5][6][7].
- Other names
- umbilical cord mesenchymal stem cellsumbilical cord-derived mesenchymal stromal cellsUC-MSCshuman umbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on umbilical cord-derived allogeneic mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived allogeneic mesenchymal stem cells.